<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ABB</journal-id><journal-title-group><journal-title>Advances in Bioscience and Biotechnology</journal-title></journal-title-group><issn pub-type="epub">2156-8456</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/abb.2013.44A004</article-id><article-id pub-id-type="publisher-id">ABB-30589</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  Fc receptors: Cell activators of antibody functions
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>arlos</surname><given-names>Rosales</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Eileen</surname><given-names>Uribe-Querol</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>División de Estudios de Posgrado e Investigación, Facultad de Odontología, Universidad Nacional Autónoma de México, Mexico City, Mexico</addr-line></aff><aff id="aff1"><addr-line>Immunology Department, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>carosal@unam.mx(AR)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>04</month><year>2013</year></pub-date><volume>04</volume><issue>04</issue><fpage>21</fpage><lpage>33</lpage><history><date date-type="received"><day>January</day>	<month>18th,</month>	<year>2013</year></date><date date-type="rev-recd"><day>March</day>	<month>12th,</month>	<year>2013</year>	</date><date date-type="accepted"><day>April</day>	<month>16th,</month>	<year>2013</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   At the onset of an infection early defense systems, such as complement, get into action. Specialized leukocytes (white blood cells) of the innate immune system, including monocytes, macrophages, and neutrophils also participate as a first line of defense against infections. These early responses are rapid but not very specific and are usually not enough to clear completely many infections. The adaptive immune system is also needed to finish the job against many microorganisms. Antibody molecules, produced during the adaptive immune response, are crucial for preventing recurrent infections. Although, IgG antibodies are essential for controlling infections, these molecules do not directly damage the microorganisms they recognize. Today, it is established that leukocytes of the innate immune system are responsible for the protective effects of these antibodies. IgG molecules bind to their cognate antigens and are in turn recognized by specific receptors (Fcγ receptors) on the membrane of leukocytes. Crosslinking these receptors on the surface of leukocytes leads to activation of several effector cell functions. These effector functions are geared toward the destruction of microbial pathogens and the induction of an inflammatory state that is beneficial during infections. However, in autoimmune diseases, antibodies can direct these effector functions against normal tissues and cause severe tissue damage. In recent years, several factors that can modulate the IgG-FcγR interaction have been elucidated. In this review, we describe the main types of Fcγ receptors, and our current view of how antibody variants interact with these receptors to initiate different cell responses. In addition, new findings on the signaling role of individual Fcγ receptors are also discussed. 
 
</p></abstract><kwd-group><kwd>Immunoglobulin; Antibody; Immunoreceptor; Neutrophil; Macrophage</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. INTRODUCTION</title><p>At the onset of an infection by different types of microorganisms, including viruses, bacteria, fungi, and protozoa, early defense systems, such as constitutive expression of antimicrobial peptides, and activation of complement get into action. These systems are rapid but not particularly specific. Specialized leukocytes (white blood cells) of the innate immune system, including monocytes, macrophages, and neutrophils also participate as a first line of defense against infections. These leukocytes can bind some microbial molecules, termed dangerand pathogen-associated molecular patterns (DAMPs and PAMPs, respectively) via numerous receptors such as the Toll-like receptor family [1,2]. In this way, leukocytes recognize microorganisms directly and prevent a massive infection [<xref ref-type="bibr" rid="scirp.30589-ref3">3</xref>]. These early responses however, are usually not enough to clear completely many infections. The adaptive immune system is also needed to finish the job against many microorganisms. Antibody molecules, produced during the adaptive immune response, are crucial for preventing recurrent infections [<xref ref-type="bibr" rid="scirp.30589-ref4">4</xref>]. At the beginning of the adaptive response, antibodies belong to the IgM class. These antibodies present low affinity for microbial antigens, but they can easily activate the classical complement pathway. Complement deposited on microorganisms can induce phagocytosis via complement receptors [5,6], or it can induce bacterial lysis via the formation of the membrane attack complex [<xref ref-type="bibr" rid="scirp.30589-ref7">7</xref>]. At later times of the adaptive response, antibodies belong mainly to the IgG class. These antibodies are of higher affinity and of much greater specificity for their particular antigen. Thus, IgG antibodies are key for controlling many microorganisms, as demonstrated by immunodeficiency disorders, with low production of this class of antibodies, in which there is increased susceptibility to microbial infections [<xref ref-type="bibr" rid="scirp.30589-ref4">4</xref>]. Although, IgG antibodies are essential for controlling infections, these molecules do not directly damage the microorganisms they recognize. Today, it is established that leukocytes of the innate immune system are responsible for the protective effects of these antibodies. IgG molecules bind to their cognate antigens via their two fragment antigen-binding (Fab) sites, and are in turn recognized by specific receptors on the membrane of leukocytes. These receptors bind the Fc (fragment crystallizable) domain of IgG; thus, they are named Fcγ receptors (FcγR) [8,9]. In this way, IgG antibodies are the bridge between the two arms of the immune system, bringing together the specificity of recognition of the adaptive immune system and the destructive potential of the cells of the innate immune system. Crosslinking these receptors on the surface of leukocytes leads to activation of several effector cell functions. Depending on the cell type, and also on the Fcγ receptor type, these functions include phagocytosis, cell degranulation, production of various cytokines and chemokines, antibody-dependent cell-mediated cytotoxicity (ADCC), and activation of genes [<xref ref-type="bibr" rid="scirp.30589-ref10">10</xref>]. These effector functions are geared toward the destruction of microbial pathogens and the induction of an inflammatory state that is beneficial during infections. However, in autoimmune diseases, antibodies can direct these effector functions against normal tissues and cause severe tissue damage [11,12]. It is then of great interest to understand how various FcγR are activated to induce these cellular functions. In recent years, several factors that can modulate the IgG-FcγR interaction have been described. These factors include, the particular IgG subclass [<xref ref-type="bibr" rid="scirp.30589-ref13">13</xref>] and the glycosylation pattern of the antibody [<xref ref-type="bibr" rid="scirp.30589-ref14">14</xref>]. In addition, other molecules, such as members of the pentraxin family can bind FcγR [15,16], and certain glycosylation variants of antibodies can bind other cell membrane receptors different from FcγR [17-19]. In this review, we describe the main types of Fcγ receptors, and our current view of how antibody variants interact with these receptors to initiate different cell responses. In addition, new findings on the signaling role of individual Fcγ receptors are also discussed.</p></sec><sec id="s2"><title>2. Fcγ RECEPTORS</title><sec id="s2_1"><title>2.1. Structure</title><p>Antibodies represent an important bridge between the specificity of the adaptive immune system, and the highly destructive mechanisms of cells of the innate immune system. Antibodies bind to microorganisms via their antigen-binding sites, and to Fc receptors on the surface of leukocytes, via their carboxyl terminal Fc portion. Receptors for the Fc portion of various immunoglobulin (Ig) classes have been described [<xref ref-type="bibr" rid="scirp.30589-ref20">20</xref>]. Fc Receptors for IgG (FcγR), for IgE (FcεR), and for IgA (FcαR) are known [<xref ref-type="bibr" rid="scirp.30589-ref20">20</xref>]. Crosslinking of Fcγ receptors with their IgG antibody ligands triggers various functions in many cells of the immune system. These cell functions include phagocytosis, cell degranulation, production of various cytokines and chemokines, ADCC, and activation of genes [10,21].</p><p>Fcγ receptors are a family of glycoproteins, part of the IgG superfamily. They consist of an IgG binding α-subunit, that usually pairs with accessory γ chains, which are important for receptor signaling (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>In humans, three classes of FcγR have been identified, FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) (<xref ref-type="fig" rid="fig1">Figure 1</xref>A) [<xref ref-type="bibr" rid="scirp.30589-ref22">22</xref>]. FcγR are coded for by different genes and differ in their relative avidity for IgG, molecular structure, and cellular distribution. FcγRI α-subunit presents three Ig-like extracellular domains, and binds monomeric IgG [<xref ref-type="bibr" rid="scirp.30589-ref23">23</xref>]. In contrast, FcγRII and FcγRIII present two Ig-like extracellular domains, and bind only multimeric immune complexes. FcγRI, expressed on monocytes, macrophages, and interferon-γ (IFN-γ)-stimulated neu-</p><p>trophils, is associated with a dimer of the common Fc receptor (FcR) gamma-chain (also named FcRγ chain). Each γ chain contains tyrosine residues that are phosphorylated upon receptor activation and become docking sites for other signaling molecules. These tyrosine residues are found within a common motif known as ITAM, for immunoreceptor tyrosine-based activation motif [24, 25]. There are several isoforms of FcγRII, derived from its three genes and from alternative splicing. FcγRII isoforms are distributed differently on hematopoietic cells. FcγRIIA and FcγRIIC are found mainly in phagocytic cells (neutrophils, monocytes, and macrophages), whereas FcγRIIB is expressed mainly in B lymphocytes [<xref ref-type="bibr" rid="scirp.30589-ref22">22</xref>]. FcγRIIB expression is inducible in phagocytic leukocytes, for the negative regulation of cell functions, such as phagocytosis [8,26]. The human FcγRIIA is a particular receptor that does not have associated FcRγ chains. FcγRIIA contains an ITAM in its cytoplasmic portion, while FcγRIIB has a different tyrosine-containing motif involved in negative signaling. This motif is known as ITIM, for immunoreceptor tyrosine-based inhibition motif [<xref ref-type="bibr" rid="scirp.30589-ref27">27</xref>]. FcγRIII has two isoforms: FcγRIIIA is a receptor with a transmembrane portion and a cytoplasmic tail, associated with an ITAM-containing homodimer of FcRγ chains on macrophages, natural killer (NK) cells, and dendritic cells. FcγRIIIA expressed on basophils and mast cells associates with a heterodimer of γ/ζ chains and an extra β chain (<xref ref-type="fig" rid="fig1">Figure 1</xref>A) [22,23]. FcγRIIIB is present exclusively on neutrophils and it is a glycosylphosphatidylinositol (GPI)-linked receptor, lacking a cytoplasmic tail. No other subunits are known to associate with it, and its signaling mechanism remains unidentified (<xref ref-type="fig" rid="fig1">Figure 1</xref>A). It is also worth noting that human FcγRIIA and FcγRIIIB are exclusive receptors that are not found in other species [<xref ref-type="bibr" rid="scirp.30589-ref28">28</xref>].</p><p>In mice, several Fcγ receptors have also been described (<xref ref-type="fig" rid="fig1">Figure 1</xref>B). These receptors are very similar, yet not identical, to the human FcγR [<xref ref-type="bibr" rid="scirp.30589-ref8">8</xref>]. FcγRI is expressed on monocytes and macrophages, and it is also associated with a dimer of FcRγ chains, which contain the ITAM motifs involved in receptor signaling. FcγRIII is a receptor with a transmembrane portion and a cytoplasmic tail, associated with a dimer of FcRγ chains, containing ITAMs. This receptor is closer to the human FcγRIIA, as revealed by the genetic structure of FcRs in various species [<xref ref-type="bibr" rid="scirp.30589-ref13">13</xref>]. FcγRIV is also an activating receptor expressed together with a dimer of FcRγ chains [<xref ref-type="bibr" rid="scirp.30589-ref29">29</xref>], and it is closer to the human FcγRIIIA (<xref ref-type="fig" rid="fig1">Figure 1</xref>B). FcγRIV may be the most relevant activating FcγR in mice, due to its ability to bind IgG2a and IgG2b with higher affinity [<xref ref-type="bibr" rid="scirp.30589-ref13">13</xref>]. FcγRIIB is the negative receptor containing an ITIM motif in its cytoplasmic tail. It is expressed mainly in B lymphocytes but also in phagocytic leukocytes and dendritic cells. FcγRIIB, described first in B lymphocytes, down regulates the activation signals from the B cell antigen receptor (BCR) to inhibit antibody production by the B cell [<xref ref-type="bibr" rid="scirp.30589-ref30">30</xref>]. This inhibitory receptor also helps to regulate initiation of other cell functions in phagocytic leukocytes and dendritic cells by creating, together with activating Fcγ receptors, a threshold for cell activation [13,31].</p></sec><sec id="s2_2"><title>2.2. Cell Expression of Fcγ Receptors</title><p>Fcγ receptors are found on many cells of the immune system, including granulocytes such as neutrophils and eosinophils; phagocytes such as neutrophils, monocytes and macrophages; and lymphocytes such as natural killer cells and B cells [<xref ref-type="bibr" rid="scirp.30589-ref23">23</xref>]. The wide variety of cellular responses regulated by Fcγ receptors is consequently not surprising. Monocytes and macrophages express all types of activating Fcγ receptors, FcγRI, FcγRII, and FcγRIII in humans, and FcγRI, FcγRIII, and FcγRIV in mice (<xref ref-type="table" rid="table1">Table 1</xref>). Murine neutrophils express FcγRIII, and FcγRIV, whereas human neutrophils express FcγRIIA and FcγRIIIB. It is noteworthy to mention that human neutrophils have the two unique FcγR, not present in neutrophils of other species. Thus, care should be taken when analyzing data derived from mouse studies of neutrophil FcγR function, since conclusions may not necessarily apply to human neutrophils. NK cells exclusively express FcγRIIIA in humans and FcγRIII in mice. Dendritic cells (DCs) also express various FcγRs, while B lymphocytes express mainly the inhibitory FcγRIIB (<xref ref-type="table" rid="table1">Table 1</xref>). Some T lymphocyte populations have also been reported to express FcγRs [32-34], but the role for these receptors in T cell function or development remains unclear and requires further studies.</p></sec><sec id="s2_3"><title>2.3. Fcγ Receptor Signaling</title><p>Crosslinking of activating Fcγ receptors with their IgG antibody ligands triggers various functions in many cells of the immune system. As mentioned before, all activateing receptors contain ITAM motifs involved in receptor signaling. The exact activation mechanism is not completely clear, but at the initial molecular events involve activation of Src family kinases followed by activation of Syk (spleen tyrosine kinase) family kinases.</p><p>The model for the initial steps of activating FcγR signaling is as follows: Upon crosslinking, the receptor associates with lipid rafts. Lipid rafts are small regions of the plasma membrane that are enriched in cholesterol and sphingolipids [<xref ref-type="bibr" rid="scirp.30589-ref35">35</xref>]. There, the receptor co-localizes with Src kinases. These kinases phosphorylate tyrosines within the ITAM. Phosphorylated tyrosines then become docking sites for Syk. This kinase then phosphorylates multiple substrates, including phosphatidylinositol 3- kinase (PI 3-K), phospholipase Cγ (PLCγ), and the adap</p><p><xref ref-type="table" rid="table1">Table 1</xref>. Fc gamma receptors.</p><p><img src="4-7300540\46565eaf-819c-4370-89d5-623ffb26124a.jpg" /></p><p><sup>a</sup>Data from [64,65]; <sup>b</sup>Data from [29,61].</p><p>or molecules SLP76 (SH2-domain-containing leukocyte protein of 76 kDa) and LAT (linker for activation of T cells) [<xref ref-type="bibr" rid="scirp.30589-ref36">36</xref>] (<xref ref-type="fig" rid="fig2">Figure 2</xref>). These molecules organize and activate several signaling pathways, depending on the cell type, leading to particular cellular responses and to transcriptional changes (<xref ref-type="fig" rid="fig2">Figure 2</xref>). For example, SLP76 seems to be important for FcγR signaling in neutrophils [<xref ref-type="bibr" rid="scirp.30589-ref37">37</xref>], while it seems to be dispensable in macrophages and NK cells [38,39]. LAT is another adaptor that seems to participate in many FcγR-mediated functions (<xref ref-type="fig" rid="fig2">Figure 2</xref>). LAT was reported to be constitutively associated with the common FcRγ chain in monocytes [<xref ref-type="bibr" rid="scirp.30589-ref40">40</xref>], and to be important for efficient phagocytosis in macrophages [<xref ref-type="bibr" rid="scirp.30589-ref40">40</xref>]. Clearly, further studies are needed to identify the particular adaptor used by each type of Fc receptor in the various leukocytes, and to connect this to a unique cell response.</p><p>The inhibitory FcγRIIB is the negative receptor containing an ITIM motif in its cytoplasmic tail instead of an ITAM sequence [<xref ref-type="bibr" rid="scirp.30589-ref41">41</xref>]. It was described first in B lymphocytes, where it down regulates the activation signals from the B cell antigen receptor (BCR) (<xref ref-type="fig" rid="fig3">Figure 3</xref>A) to inhibit antibody production by the B cell [<xref ref-type="bibr" rid="scirp.30589-ref30">30</xref>]. Contrary to the activating receptors that engage several kinases, this inhibitory receptor signals by activation of phosphatases. Inositol 5-phosphatase (SHIP1) is the main enzyme activated upon crosslinking of FcγRIIB and BCR (<xref ref-type="fig" rid="fig3">Figure 3</xref>B) [<xref ref-type="bibr" rid="scirp.30589-ref27">27</xref>]. This phosphatase binds via its SH2 domain, to the phosphorylated tyrosines within the ITIM sequence of FcγRIIB. SHIP1 transforms phosphatidylinositol-3,4,5-triphosphate (PIP<sub>3</sub>) the main product of PI 3-K, into phosphatidylinositol-3,4-biphosphate (PIP<sub>2</sub>); pre-</p><p>venting in this way the stimulation of key activating enzymes such as Akt, Btk, and PLCγ (<xref ref-type="fig" rid="fig3">Figure 3</xref>B).</p></sec><sec id="s2_4"><title>2.4. Coexpression of Fcγ Receptors and Threshold for Cell Activation</title><p>As indicated above, different leukocytes express more than one activating FcγR (<xref ref-type="table" rid="table1">Table 1</xref>), and most of these cells also express at the same time the inhibitory FcγRIIB. NK cells are particular leukocytes in this respect, because they only express FcγRIIIA in humans and FcγRIII in mice. The coexpression of both activating and inhibitory FcγR results in simultaneous triggering of activating and inhibitory signal transduction pathways (<xref ref-type="fig" rid="fig4">Figure 4</xref>A). Thus, a particular cell will respond when the sum of activating and inhibiting signals reach a threshold of activation that is determined by the relative expression of both types of FcγR (<xref ref-type="fig" rid="fig4">Figure 4</xref>B). The importance of the inhibitory FcγRIIB in regulating many IgG-mediated responses in different leukocytes was made evident in FcγRIIB-deficient mice, which showed enhanced activity of many IgG-mediated cell responses including: phagocytosis, immune complex-mediated inflammation, IgG-</p><p>mediated passive and active anaphylaxis, and IgE-mediated anaphylaxis [42,43]. They also showed enhanced dendritic cell maturation, and antigen presentation [44-46]. These results thus confirmed that FcγRIIB regulates initiation of cell functions by generating, together with activating Fcγ receptors, a threshold for cell activation [31, 47].</p></sec><sec id="s2_5"><title>2.5. Genetic Structure and Polymorphisms</title><p>Analysis of FcγR genes in different species has identified</p><p>orthologous receptors between mice and humans. The similarities come from gene localization and also from sequence homology of the extracellular portion of the receptors [8,13]. Therefore, the high affinity receptors FcγRIA and FcRI, the low affinity receptors FcγRIIA and FcγRIII, and also the low affinity receptors FcγRIIIA and FcγRIV cluster in the same area of chromosome 1 (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Similarly, the inhibitory FcγRIIB gene maps to the same chromosome region, both in mice and humans (<xref ref-type="fig" rid="fig5">Figure 5</xref>). In addition, the human FcγRIIA and mouse FcγRIII, as well as the human FcγRIIIA and mouse FcγRIV, present high sequence homology in their extracellular domains [<xref ref-type="bibr" rid="scirp.30589-ref13">13</xref>]. Despite this similarity, the receptors are not equivalent, since important differences have been detected between mice and human responses to IgG. For example, the human FcγRI binds the IgG1 and IgG3 subclasses with high affinity, while the mouse FcγRI only binds IgG2a with high affinity (<xref ref-type="table" rid="table1">Table 1</xref>). In addition, the mouse FcγRIV is also able to bind IgE, while the human FcγRIIIA is not [48,49].</p><p>In addition, there are several polymorphisms in the human FcγRII and FcγRIII. For FcγRIIA two allelic variants exist expressing either arginine or histidine at position 131 [50,51]. For FcγRIIIA also allelic variants exist expressing either valine or phenylalanine at position 158 [52,53]. Similarly, for FcγRIIIB on neutrophils, two isoforms exist, the NA1 and NA2 allotypes [<xref ref-type="bibr" rid="scirp.30589-ref54">54</xref>]. These isoforms differ by five nucleotides and four amino acids, with NA2 containing two additional N-linked glycosylation sites. These differences affect the capacity of FcγRIIIB</p><p>to interact with human IgG. Therefore, neutrophils from individuals who are homozygous for the NA1 allele have better phagocytosis of IgG-opsonized targets than do neutrophils from NA2-homozygous individuals [55,56]. These multiple FcγR and their allelic variants vary greatly in their affinity for different IgG classes [<xref ref-type="bibr" rid="scirp.30589-ref57">57</xref>]. Thus, a great interest exists to understand how different IgG molecules engage different FcγR to activate the multiple cell responses associated with antibodies Fcγ receptor signaling.</p></sec></sec><sec id="s3"><title>3. IgG-MEDIATED CELL FUNCTIONS</title><sec id="s3_1"><title>3.1. Fcγ Receptor Affinity for IgG</title><p>A single antibody molecule does not bind to Fcγ recaptors. However, antigen-antibody complexes promote many low affinity interactions between FcγR on the surface of leukocytes and antibody complexes. The low affinity of antibodies for individual leukocyte FcγR prevents recaptors from binding antibodies in the absence of antigen, thus reducing the chance of immune cell activation when there is not an infection. Immune complexes induce the crosslinking of FcγR to activate the many different antibody-mediated cell responses. Immune complexes are clearly of different kinds, since they are formed by different classes of antibodies, and in vivo studies have suggested that the different IgG classes have different activities. For example, IgG2b/c was better in eliminating B cells [<xref ref-type="bibr" rid="scirp.30589-ref58">58</xref>] and T cell lymphomas [<xref ref-type="bibr" rid="scirp.30589-ref59">59</xref>] than IgG1. Likewise, using class-switch variants of anti-erythrocyte antibodies it was found that IgG2a and IgG2b were better in mediating phagocytosis of opsonized erythrocytes than IgG1 and IgG3 [60,61]. Also, polioencephalomyelitis induced by infection with lactate dehydrogenaseelevating virus (LDV) was delayed much better by IgG2a anti-LDV antibodies than any other IgG class of antiLDV antibodies [<xref ref-type="bibr" rid="scirp.30589-ref62">62</xref>]. In addition, the severity of glomerular inflammation was greater for IgG2a, followed by IgG2b and finally IgG1 [<xref ref-type="bibr" rid="scirp.30589-ref63">63</xref>]. All these reports confirmed that different IgG classes mediate different cellular responses in vivo through Fcγ receptors.</p><p>Because, immune complexes of different kinds induce different cell responses, there has been a great interest in determining which type of IgG binds to which FcγR and what particular receptor is involved in mediating the activity of particular IgG classes. Early studies showed that there is a high affinity receptor for IgG (FcγRI), which binds preferably to IgG1 in humans and IgG2a in mice [64,65]. This receptor is saturated with serum IgG on leukocytes in the blood. As mentioned before, the other receptors have only low affinity and can bind to IgG only in the form of immune complexes (<xref ref-type="table" rid="table1">Table 1</xref>) [64,65]. In addition, it was clearly established that most FcγR have a binding preference for IgG1 and IgG3 over the other classes of IgG (<xref ref-type="table" rid="table1">Table 1</xref>). Similarly, in mice it was found that IgG1 binds only to FcγRIII, while IgG2a binds to all types of activating FcγR, and IgG2b binds to FcγRIII and FcγRIV. IgG3 does not seem to bind significantly to any of the FcγR (<xref ref-type="table" rid="table1">Table 1</xref>) [29,61]. In agreement with these data, IgG1 activity was lost in mice deficient in FcγRIII [61,66]. For IgG2a and IgG2b, however the correlation with particular Fcγ receptors is not as simple. In some model systems the activity of these IgG classes was lost in FcγRIII-deficient mice, while it was not in others [<xref ref-type="bibr" rid="scirp.30589-ref13">13</xref>]. In a model of autoimmune hemolytic anemia, IgG2amediated response was highly dependent on FcγRIII, but also FcγRI and FcγRIV contributed to the development of severe anemia [<xref ref-type="bibr" rid="scirp.30589-ref67">67</xref>]. In another model of arthritis, mice deficient in FcγRI showed reduced cartilage destruction, and impaired protection from a bacterial infection, indicating the prominent role of FcγRI in IgG2a-dependent immune functions [<xref ref-type="bibr" rid="scirp.30589-ref68">68</xref>]. Thus, IgG2a used all activating Fcγ receptors with important contribution from FcγRI and FcγRIII. Similarly, for IgG2b a particular interaction with a particular Fcγ receptor cannot be clearly established. In models of IgG2b-dependent B cell depletion [<xref ref-type="bibr" rid="scirp.30589-ref69">69</xref>], and nephrotoxic nephritis [<xref ref-type="bibr" rid="scirp.30589-ref70">70</xref>], inhibition of FcγRIV prevented B cell destruction and kidney inflammation, suggesting a central role for FcγRIV in IgG2b-mediated functions. However, in models of IgG2b-dependent autoimmune hemolytic anemia [<xref ref-type="bibr" rid="scirp.30589-ref67">67</xref>], acute glomerular inflammation [<xref ref-type="bibr" rid="scirp.30589-ref63">63</xref>], or acute lung injury [<xref ref-type="bibr" rid="scirp.30589-ref71">71</xref>], FcγRIV and also FcγRIII were important for the activity of this IgG class. Thus, an order of activity is observed among the different IgG classes, and a preference of engagement with particular Fcγ receptors.</p><p>Part of the mechanism used to create this IgG-FcγR selectivity is revealed by studies that measured the affinities of IgG classes toward both activating Fcγ recaptors and the inhibitory FcγRIIB [<xref ref-type="bibr" rid="scirp.30589-ref13">13</xref>]. In this way, it was found that IgG1 has higher affinity for the inhibitory FcγRIIB than for the activating FcγRIII (<xref ref-type="fig" rid="fig6">Figure 6</xref>A)generating a high threshold for activation. In contrast, IgG2a and IgG2b have higher affinity for the activating FcγRIV than for the inhibitory FcγRIIB (<xref ref-type="fig" rid="fig6">Figure 6</xref>B), generating a lower threshold for activation. Thus, certain classes of IgG, such as IgG1, are more dependent on the signaling from the inhibitory receptor. In agreement with this view, deletion of the inhibitory FcγRIIB increased IgG1 activity in models of platelet depletion and tumor cell killing [<xref ref-type="bibr" rid="scirp.30589-ref61">61</xref>]. It is important to note that this model for IgG-FcγR selectivity is not static and can be modulated by other factors, such as the pattern of FcγR expression on the different leukocytes (<xref ref-type="table" rid="table1">Table 1</xref>), and cytokines that can modify FcγR expression (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Thus, Th1-type cytokines such as interferon-γ, and the anaphylatoxin C5a upregulate activating FcγRs expression and downregulate FcγRIIB expression [72,73], whereas Th2-type cytokines, such as interleukin (IL)-4, IL-10, and transforming growth factor-beta (TGF-β) upregulate FcγRIIB expression [8,74].</p></sec><sec id="s3_2"><title>3.2. Each FcγR Initiates Particular Signaling Pathways That Lead to Unique Cell Responses</title><p>All the reports previously described have confirmed that different IgG classes mediate different cellular responses in vivo by engaging particular Fcγ receptors depending on the relative affinity of these receptors for a particular</p><p>IgG class. However, these findings do not explain what cell response is activated in response to a particular type of Fcγ receptor. One possibility is that each leukocyte is already programmed to respond in a certain way when immune complexes crosslink its Fcγ receptors. Another possibility is that each FcγR signals differently to initiate a particular cell response. The first possibility is not very likely because a particular leukocyte can respond with various cell functions, and also because the same class of IgG induces different responses in different leukocytes. The idea that each FcγR is able to initiate a particular cell response is supported by recent reports where individual FcγR were crosslinked on human neutrophils. As described above, human neutrophils express only two FcγR, FcγRIIA and FcγRIIIB [<xref ref-type="bibr" rid="scirp.30589-ref28">28</xref>]. These receptors are different in the way they are anchored to the cell membrane. FcγRIIA has a typical transmembrane and cytoplasmic tail containing an ITAM for signaling. In contrast, FcγRIIIB is a GPI-linked receptor, lacking a cytoplasmic tail, and its signaling mechanism remains unidentified. However, early reports indicated that both FcγR are capable of signaling and inducing particular responses [<xref ref-type="bibr" rid="scirp.30589-ref75">75</xref>]. More recently, it was found that FcγRIIA, but not FcγRIIIB could induce an increase in L-selectin expression [<xref ref-type="bibr" rid="scirp.30589-ref76">76</xref>]. Opposite to this, FcγRIIIB, but not FcγRIIA, was able to activate β1 integrins [<xref ref-type="bibr" rid="scirp.30589-ref77">77</xref>]. In addition, when the major cell response of neutrophils, arguably phagocytosis, was examined, FcγRIIA was the predominant FcγR mediating this response. FcγRIIIB contribution to phagocytosis was minimal [<xref ref-type="bibr" rid="scirp.30589-ref78">78</xref>]. In complete contrast, FcγRIIIB signaling to the neutrophil nucleus was much more efficient than FcγRIIA signaling. FcγRIIIB, but not FcγRIIA, promoted a robust increase in phosphorylated ERK in the nucleus, and also efficient phosphorylation of the nuclear factor Elk-1 [<xref ref-type="bibr" rid="scirp.30589-ref79">79</xref>]. Interestingly, the FcγRIIA signaling pathway resembles the classical ITAM-mediated pathway (<xref ref-type="fig" rid="fig2">Figure 2</xref>) [<xref ref-type="bibr" rid="scirp.30589-ref5">5</xref>], while FcγRIIIB signaling pathway remains a mystery (<xref ref-type="fig" rid="fig8">Figure 8</xref>). Taken together, these reports strongly support the hypothesis that each FcγR is capable of initiating particular signaling pathways that lead to unique cell responses.</p></sec></sec><sec id="s4"><title>4. EFFECT OF ANTIBODY GLYCOSYLATION ON Fc RECEPTOR FUNCTION</title><p>All antibodies are glycoproteins with various carbohydrate side chains attached to the protein backbone. The immunoglobulin classes IgM, IgA, and IgE have several exposed carbohydrate side chains. In contrast, IgG molecules have one carbohydrate side chain. This carbohydrate (sugar) side chain is important for IgG function. Deletion of the sugar side chain results in an altered conformation of the antibody molecule and in deficient binding to Fcγ receptors [<xref ref-type="bibr" rid="scirp.30589-ref80">80</xref>]. This carbohydrate domain is heterogeneous in its sugar composition. More than 30 different glycosylation variants of IgG can be found in serum of a healthy human or mouse individuals [<xref ref-type="bibr" rid="scirp.30589-ref14">14</xref>]. This heterogeneity is formed by variable addition of sugar residues such as sialic acid, N-acetylglucosamine, galactose and fucose in straight or branching patterns. Although heterogeneous, the pattern of glycosylation seems to change in various physiological conditions. For example, terminal galactose and sialic acid residues were reduced in active autoimmune disease [18,81], while they were increased during pregnancy [82,83]. It is not clear what these changes in the glycosylation pattern</p><p>represent, but it seems that they can modulate IgG activity [<xref ref-type="bibr" rid="scirp.30589-ref84">84</xref>]. In contrast, IgG antibodies with reduced fucose residues presented higher affinity for human FcRγIIIA and its mouse ortholog FcγRIV and showed improved antibody-dependent cellular toxicity against various tumor cells [61,85,86]. IgG antibodies with high levels of terminal sialic acid presented lower affinity for Fcγ receptors and also reduced inflammatory activity [18,87, 88]. In addition, IgG antibodies with abundant sialic can bind to other cellular receptors different from Fc receptors. SIGNR-1 (specific ICAM-3 grabbing nonintegrin related 1) and its human ortholog DC-SIGN (dendritic cell specific ICAM-3 grabbing nonintegrin) were identified as receptors for sialic acid rich IgG [<xref ref-type="bibr" rid="scirp.30589-ref87">87</xref>]. Moreover, this subpopulation of antibodies was also suggested to be responsible for the anti-inflammatory activity of intravenous Ig (IVIg) therapy, because in SIGNR-1 knockout mice, IVIg did not show an anti-inflammatory effect in a model of rheumatoid arthritis [<xref ref-type="bibr" rid="scirp.30589-ref87">87</xref>]. IVIg therapy that consists on administration of high doses of pooled serum IgG from many different donors has been used for many years to treat various autoimmune diseases such as rheumatoid arthritis and thrombocytopenia [<xref ref-type="bibr" rid="scirp.30589-ref19">19</xref>]. In addition, it has been reported that IVIg therapy can change the threshold for activation of cells by upregulation of the inhibitory FcγRIIB and downregulation of activating FcγR in some mouse models and in patients with chronic inflammatory demyelinating polyneuropathy [70,89,90]. Thus, glycosylation patterns are critical for binding to particular Fcγ receptors and other novel antibody receptors. These reports underline the need of further studies on antibody-Fc receptor interactions to better understand the multiple effects of antibody molecules.</p></sec><sec id="s5"><title>5. NEW LIGANDS FOR Fcγ RECEPTORS</title><p>Antibodies are the bona fide ligands for Fc receptors. However, some recent reports have identified other molecules different from IgG that can bind Fcγ receptors and can also activate the cell functions characteristic of antibodies. Two members of the pentraxin superfamily [<xref ref-type="bibr" rid="scirp.30589-ref91">91</xref>], which are multimeric cyclic proteins, are reported to bind human and mouse Fcγ receptors. These pentraxins are C-reactive protein (CRP) and serum amyloid P (SAP) [92-95]. These proteins are usually not found in serum of healthy individuals, but they are rapidly expressed in large amounts during inflammation and microbial infections. CRP and SAP are capable of binding to several microorganisms including bacteria and fungi and thus targeting them for phagocytosis by neutrophils and macrophages [92,96]. These reports suggest that these pentraxin proteins behave like antibodies recognizing foreign antigens on pathogens and directing them to cells of the innate immune system [<xref ref-type="bibr" rid="scirp.30589-ref16">16</xref>]. In support of this idea, it was also found that Fcγ receptor uptake of CRP-opsonized Streptococcus pneumoniae increased the immune response against these bacteria [<xref ref-type="bibr" rid="scirp.30589-ref95">95</xref>]. Moreover, CRP also seems to have an anti-inflammatory effect mediated by Fcγ receptors. In FcγR-deficient mice, administration of CRP did not protect from nephrotoxic nephritis or immune thrombocytopenia [94,97].</p></sec><sec id="s6"><title>6. CONCLUSION</title><p>Fc Receptors expressed in a wide variety of leukocytes are capable of activating in response to various antibodies different cellular responses of great importance for host defense and for immune regulation. The different subclasses of IgG antibodies are recognized by Fcγ receptors with different affinities. Also singular Fcγ receptors seem to activate particular cell responses. This provides two ways for modulating cellular responses. In addition, expression of both activating and inhibitory Fcγ receptors establishes a threshold for activation of innate immune cells. Thus, Fcγ receptors are responsible of controlling the intensity of the immune response and of preventing unnecessary activation of innate immune cells, which might damage normal tissues. Novel glycosylation variants of IgG that bind Fcγ receptors with different affinities have been identified and also the anti-inflamematory activity of intravenous IgG therapy. Finally, novel receptors for antibody variants and novel Fcγ receptor ligands are been recognized. These new information together with new studies on IgG-Fcγ receptor interactions will certainly help us to develop new ways of controlling not only antibody-mediated effector functions directed against pathogens and tumors, but also the exaggerated antibody-mediated cell responses associated with auto-immunity.</p></sec><sec id="s7"><title>7. ACKNOWLEDGEMENTS</title><p>Research in the authors’ laboratory is supported by grant 168098 from Consejo Nacional de Ciencia y Tecnolog&#237;a, Mexico, and by grants IB200811, IA202013-2 (to EUQ), and IN205311-2 (to CR) from Direcci&#243;n General de Asuntos del Personal Acad&#233;mico, Universidad Nacional Aut&#243;noma de M&#233;xico, Mexico</p></sec><sec id="s8"><title>REFERENCES</title></sec><sec id="s9"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.30589-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Akira, S., Uematsu, S. and Takeuchi, O. (2006) Pathogen recognition and innate immunity. Cell, 124, 783-801. 
doi:10.1016/j.cell.2006.02.015</mixed-citation></ref><ref id="scirp.30589-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kawai, T. and Akira, S. (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity, 34, 637-650. 
doi:10.1016/j.immuni.2011.05.006</mixed-citation></ref><ref id="scirp.30589-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Iwasaki, A. and Medzhitov, R. (2010) Regulation of adaptive immunity by the innate immune system. Science, 327, 291-295. doi:10.1126/science.1183021</mixed-citation></ref><ref id="scirp.30589-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Ballow, M. (2002) Primary immunodeficiency disorders: Antibody deficiency. Journal of Allergy and Clinical Immunology, 109, 581-591. 
doi:10.1067/mai.2002.122466</mixed-citation></ref><ref id="scirp.30589-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rosales, C. (2007) Fc receptor and integrin signaling in phagocytes. Signal Transduction, 7, 386-401. 
doi:10.1002/sita.200700141</mixed-citation></ref><ref id="scirp.30589-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tohyama, Y. and Yamamura, H. (2006) Complement-mediated phagocytosis—The role of Syk. IUBMB Life, 58, 304-308. doi:10.1080/15216540600746377</mixed-citation></ref><ref id="scirp.30589-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Heyman, B. (2000) Regulation of antibody responses via antibodies, complement, and Fc receptors. Annual Review of Immunology, 18, 709-737. 
doi:10.1146/annurev.immunol.18.1.709</mixed-citation></ref><ref id="scirp.30589-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Nimmerjahn, F. and Ravetch, J. (2008) Fcγ receptors as regulators of immune responses. Nature Reviews Immunology, 8, 34-47. doi:10.1038/nri2206</mixed-citation></ref><ref id="scirp.30589-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Powell, M.S. and Hogarth, P.M. (2008) Fc receptors. Advances in Experimental Medicine and Biology, 640, 22- 34. doi:10.1007/978-0-387-09789-3_3</mixed-citation></ref><ref id="scirp.30589-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">García-García, E. and Rosales, C. (2009) Fc receptor signaling in leukocytes: Role in host defense and immune regulation. Current Immunology Reviews, 5, 227-242. 
doi:10.2174/157339509788921229</mixed-citation></ref><ref id="scirp.30589-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hogarth, P. (2002) Fc receptors are major mediators of antibody based inflammation in autoimmunity. Current Opinion in Immunology, 14, 798-802. 
doi:10.1016/S0952-7915(02)00409-0</mixed-citation></ref><ref id="scirp.30589-ref12"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takai</surname><given-names> T. </given-names></name>,<etal>et al</etal>. (<year>2002</year>)<article-title>Roles of Fc receptors in autoimmunity</article-title><source> Nature Reviews Immunology</source><volume> 2</volume>,<fpage> 580</fpage>-<lpage>592</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Nimmerjahn, F. and Ravetch, J. (2006) Fcγ receptors: Old friends and new family members. Immunity, 24, 19-28. 
doi:10.1016/j.immuni.2005.11.010</mixed-citation></ref><ref id="scirp.30589-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Arnold, J., Wormald, M., Sim, R., Rudd, P. and Dwek, R. (2007) The impact of glycosylation on the biological function and structure of human immunoglobulins. Annual Review of Immunology, 25, 21-50. 
doi:10.1146/annurev.immunol.25.022106.141702</mixed-citation></ref><ref id="scirp.30589-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Jinghua, L., Lorraine, L.M., Kristopher, D.M., Carolyn, M., Terry, W.D.C. and Peter, D.S. (2008) Structural recognition and functional activation of FcγR by innate pentraxins. Nature, 456, 989-992. 
doi:10.1038/nature07468</mixed-citation></ref><ref id="scirp.30589-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Marnell, L., Mold, C. and Du Clos, T. (2005) C-reactive protein: Ligands, receptors and role in inflammation. Clinical Immunology, 117, 104-111. 
doi:10.1016/j.clim.2005.08.004</mixed-citation></ref><ref id="scirp.30589-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Anthony, R., Nimmerjahn, F., Ashline, D., Reinhold, V., Paulson, J. and Ravetch, J. (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science, 320, 373-376. doi:10.1126/science.1154315</mixed-citation></ref><ref id="scirp.30589-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kaneko, Y., Nimmerjahn, F. and Ravetch, J. (2006) Anti- inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science, 313, 670-673. 
doi:10.1126/science.1129594</mixed-citation></ref><ref id="scirp.30589-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Nimmerjahn, F. and Ravetch, J. (2008) Anti-inflammatory actions of intravenous immunoglobulin. Annual Review of Immunology, 26, 513-533. 
doi:10.1146/annurev.immunol.26.021607.090232</mixed-citation></ref><ref id="scirp.30589-ref20"><label>20</label><mixed-citation publication-type="book" xlink:type="simple">Jones, S.L., Lindberg, F.P. and Brown, E.J. (1999) Phagocytosis. In: Paul, W.E., Ed., Fundamental Immunology, Lippincott-Raven Publishers, Philadelphia, 997-1020.</mixed-citation></ref><ref id="scirp.30589-ref21"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sánchez-Mejorada</surname><given-names> G. and Rosales</given-names></name>,<name name-style="western"><surname> C. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1998</year>)<article-title>Signal transduction by immunoglobulin Fc receptors</article-title><source> Journal of Leukocyte Biology</source><volume> 63</volume>,<fpage> 521</fpage>-<lpage>533</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ravetch, J.V. and Bolland, S. (2001) IgG Fc receptors. Annual Review of Immunology, 19, 275-290. 
doi:10.1146/annurev.immunol.19.1.275</mixed-citation></ref><ref id="scirp.30589-ref23"><label>23</label><mixed-citation publication-type="book" xlink:type="simple">Ravetch, J.V. (2003) Fc receptors. In: Paul, W.E., Ed., Fundamental Immunology, Lippincott Williams &amp; Wilkins, Philadelphia, 631-684.</mixed-citation></ref><ref id="scirp.30589-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Fodor, S., Jakus, Z. and Mócsai, A. (2006) ITAM-based signaling beyond the adaptive immune response. Immunology Letters, 104, 29-37. 
doi:10.1016/j.imlet.2005.11.001</mixed-citation></ref><ref id="scirp.30589-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Underhill, D.M. and Goodridge, H.S. (2007) The many faces of ITAMs. Trends in Immunology, 28, 66-73. 
doi:10.1016/j.it.2006.12.004</mixed-citation></ref><ref id="scirp.30589-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Tridandapani, S., Siefker, K., Teillaud, J.-L., Carter, J.E., Wewers, M.D. and Anderson, C.L. (2002) Regulated expression and inhibitory function of FcγRIIb in human monocytic cells. The Journal of Biological Chemistry, 277, 5082-5089. doi:10.1074/jbc.M110277200</mixed-citation></ref><ref id="scirp.30589-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Da&amp;#235ron, M. and Lesourne, R. (2006) Negative signaling in Fc receptor complexes. Advances in Immunology, 89, 39-86. doi:10.1016/S0065-2776(05)89002-9</mixed-citation></ref><ref id="scirp.30589-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Willcocks, L.C., Smith, K.G. and Clatworthy, M.R. (2009) Low-affinity Fcγ receptors, autoimmunity and infection. Expert Reviews in Molecular Medicine, 11, e24. 
doi:10.1017/S1462399409001161</mixed-citation></ref><ref id="scirp.30589-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Nimmerjahn, F., Bruhns, P., Horiuchi, K. and Ravetch, J. (2005) FcγRIV: A novel FcR with distinct IgG subclass specificity. Immunity, 23, 41-51. 
doi:10.1016/j.immuni.2005.05.010</mixed-citation></ref><ref id="scirp.30589-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Stefanescu, R.N., Olferiev, M., Liu, Y. and Pricop, L. (2004) Inhibitory Fc gamma receptors: From gene to disease. Journal of Clinical Immunology, 24, 315-326. 
doi:10.1023/B:JOCI.0000029105.47772.04</mixed-citation></ref><ref id="scirp.30589-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Boruchov, A., Heller, G., Veri, M., Bonvini, E., Ravetch, J. and Young, J. (2005) Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. The Journal of Clinical Investigation, 115, 2914-2923. 
doi:10.1172/JCI24772</mixed-citation></ref><ref id="scirp.30589-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Anderson, C. and Grey, H. (1974) Receptors for aggregated IgG on mouse lymphocytes: Their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes. The Journal of Experimental Medicine, 139, 1175-1188. doi:10.1084/jem.139.5.1175</mixed-citation></ref><ref id="scirp.30589-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Leclerc, J., Plater, C. and Fridman, W. (1977) The role of the Fc receptor (FcR) of thymus-derived lymphocytes. I. Presence of FcR on cytotoxic lymphocytes and absence of direct role in cytotoxicity. European Journal of Immunology, 7, 543-548.doi:10.1002/eji.1830070810</mixed-citation></ref><ref id="scirp.30589-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Stout, R.D. and Herzenberg, L.A. (1975) The Fc receptor on thymus-derived lymphocytes. I. detection of a subpopulation of murine T lymphocytes bearing the Fc receptor. The Journal of Experimental Medicine, 142, 611- 621. doi:10.1084/jem.142.3.611</mixed-citation></ref><ref id="scirp.30589-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Rajendran, L. and Simons, K. (2005) Lipid rafts and membrane dynamics. Journal of Cell Science, 118, 1099-1102. 
doi:10.1242/jcs.01681</mixed-citation></ref><ref id="scirp.30589-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Bezman, N. and Koretzky, G.A. (2007) Compartamentalization of ITAM and integrin signaling by adapter molecules. Immunology Review, 218, 9-28. 
doi:10.1111/j.1600-065X.2007.00541.x</mixed-citation></ref><ref id="scirp.30589-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Newbrough, S.A., Mocsai, A., Clemens, R.A., Wu, J.N., Silverman, M.A., Singer, A.L., Lowell, C.A. and Koretzky, G.A. (2003) SLP-76 regulates Fcγ receptor and integrin signaling in neutrophils. Immunity, 19, 761-769. 
doi:10.1016/S1074-7613(03)00305-4</mixed-citation></ref><ref id="scirp.30589-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Myung, P.S., Clements, J.L., White, D.W., Malik, Z.A., Cowdery, J.S., Allen, L.-A.H., Harty, J.T., Kusner, D.J. and Koretzky, G.A. (2000) In vitro and in vivo macrophage function can occur independently of SLP-76. International Immunology, 12, 887-897. 
doi:10.1093/intimm/12.6.887</mixed-citation></ref><ref id="scirp.30589-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Nichols, K.E., Haines, K., Myung, P.S., Newbrough, S., Myers, E., Jumaa, H., Shedlock, D.J., Shen, H. and Koretzky, G.A. (2004) Macrophage activation and Fcγ receptor-mediated signaling do not require expression of the SLP-76 and SLP-65 adaptors. Journal of Leukocyte Biology, 75, 541-552. doi:10.1189/jlb.0703312</mixed-citation></ref><ref id="scirp.30589-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Tridandapani, S., Lyden, T.W., Smith, J.L., Carter, J.E., Coggeshall, K.M. and Anderson, C.L. (2000) The adapter protein LAT enhances Fcγ Receptor-mediated signal transduction in myeloid cells. The Journal of Biological Chemistry, 275, 20480-20487. 
doi:10.1074/jbc.M909462199</mixed-citation></ref><ref id="scirp.30589-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Da&amp;#235ron, M., Latour, S., Malbec, O., Espinosa, E., Pina, P., Pasmans, S. and Fridman, W.H. (1995) The same tyrosine-based inhibition motif, in the intracytoplasmic domain of FcγRIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity, 3, 635-646. 
doi:10.1016/1074-7613(95)90134-5</mixed-citation></ref><ref id="scirp.30589-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Bolland, S. and Ravetch, J. (2000) Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis. Immunity, 13, 277-285. 
doi:10.1016/S1074-7613(00)00027-3</mixed-citation></ref><ref id="scirp.30589-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Takai, T., Ono, M., Hikida, M., Ohmori, H. and Ravetch, J. (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature, 379, 346-349. 
doi:10.1038/379346a0</mixed-citation></ref><ref id="scirp.30589-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Dhodapkar, K., Banerjee, D., Connolly, J., Kukreja, A., Matayeva, E., Veri, M., Ravetch, J., Steinman, R. and Dhodapkar, M. (2007) Selective blockade of the inhibitory Fcγ receptor (FcγRIIB) in human dendritic cells and monocytes induces a type I interferon response program. The Journal of Experimental Medicine, 204, 1359-1369. 
doi:10.1084/jem.20062545</mixed-citation></ref><ref id="scirp.30589-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Dhodapkar, K., Kaufman, J., Ehlers, M., Banerjee, D., Bonvini, E., Koenig, S., Steinman, R., Ravetch, J. and Dhodapkar, M. (2005) Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 102, 2910-2915. doi:10.1073/pnas.0500014102</mixed-citation></ref><ref id="scirp.30589-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Kalergis, A. and Ravetch, J. (2002) Inducing tumor immunity through the selective engagement of activating Fc gamma receptors on dendritic cells. The Journal of Experimental Medicine, 195, 1653-1659. 
doi:10.1084/jem.20020338</mixed-citation></ref><ref id="scirp.30589-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Nimmerjahn, F. and Ravetch, J.V. (2010) Antibody-mediated modulation of immune responses. Immunology Review, 236, 265-275. 
doi:10.1111/j.1600-065X.2010.00910.x</mixed-citation></ref><ref id="scirp.30589-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Hirano, M., Davis, R.S., Fine, W.D., Nakamura, S., Shimizu, K.Y., H., kato, K., Stephan, R.P. and Cooper, M.D. (2007) IgEb immune complexes activate macrophages through FcγRIV binding. Nature Immunology, 8, 762-771. 
doi:10.1038/ni1477</mixed-citation></ref><ref id="scirp.30589-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Mancardi, D., Iannascoli, B., Hoos, S., England, P., Da&amp;#235ron, M. and Bruhns, P. (2008) FcγRIV is a mouse IgE receptor that resembles macrophage FcεRI in humans and promotes IgE-induced lung inflammation. The Journal of Clinical Investigation, 118, 3738-3750. 
doi:10.1172/JCI36452</mixed-citation></ref><ref id="scirp.30589-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Salmon, J.E., Edberg, J.C., Brogle, N.L. and Kimberly, R.P. (1992) Allelic polimorphisms of human Fcγ receptor IIA and Fcγ receptor IIIB. Independent mechanisms for differences in human phagocyte function. The Journal of Clinical Investigation, 89, 1274-1281. 
doi:10.1172/JCI115712</mixed-citation></ref><ref id="scirp.30589-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Tax, W.J.M., Willems, H.W., Reekers, P.P.M., Capel, P.J.A. and Koene, R.A.P. (1983) Polymorphism in mitogenic effect of IgG1 monoclonal antibodies against T3 antigen on human T cells. Nature, 304, 445-447. 
doi:10.1038/304445a0</mixed-citation></ref><ref id="scirp.30589-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Koene, H.R., Kleijer, M., Swaak, A.J.G., Sullivan, K.E., Bijl, M., Petri, M.A., Kallenberg, C.G.M., Roos, D., von dem Borne, A.E.G.K. and de Haas, M. (1998) The FcγRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis &amp; Rheumatism, 41, 1813-1818. 
doi:10.1002/1529-0131(199810)41:10&lt;1813::AID-ART13&gt;3.0.CO;2-6</mixed-citation></ref><ref id="scirp.30589-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Wu, J., Edberg, J.C., Redecha, P.B., Bansal, V., Guyre, P.M., Coleman, K., Salmon, J.E. and Kimberly, R.P. (1997) A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. The Journal of Clinical Investigation, 100, 1059-1070. 
doi:10.1172/JCI119616</mixed-citation></ref><ref id="scirp.30589-ref54"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huizinga</surname><given-names> T.W.J.</given-names></name>,<name name-style="western"><surname> Kleijer</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Tetteroo</surname><given-names> P.A.T.</given-names></name>,<name name-style="western"><surname> Roos</surname><given-names> D. and von dem Borne</given-names></name>,<name name-style="western"><surname> A.E.G.K. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>Biallelic neutrophil Na-antigen system is associated with a polymorphism on the phospho-inositol-linked Fcγ receptor III (CD16)</article-title><source> Blood</source><volume> 75</volume>,<fpage> 213</fpage>-<lpage>217</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Hatta, Y., Tsuchiya, N., Ohashi, J., Matsushita, M., Fujiwara, K., Hagiwara, K., Juji, T. and Tokunaga, K. (1999) Association of Fc gamma receptor IIIB, but not of Fc gamma receptor IIA and IIIA, polymorphisms with systemic lupus erythematosus in Japanese. Genes &amp; Immunity, 1, 53-60. doi:10.1038/sj.gene.6363639</mixed-citation></ref><ref id="scirp.30589-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Salmon, J.E., Edberg, J.C. and Kimberly, R.P. (1990) Fcγ receptor III on human neutrophils. Allelic variants have functionally distinct capacities. The Journal of Clinical Investigation, 85, 1287-1295. doi:10.1172/JCI114566</mixed-citation></ref><ref id="scirp.30589-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Bruhns, P., Iannascoli, B., England, P., Mancardi, D., Fernandez, N., Jorieux, S. and Da&amp;#235ron, M. (2009) Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood, 113, 3716-3725. doi:10.1182/blood-2008-09-179754</mixed-citation></ref><ref id="scirp.30589-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Uchida, J., Hamaguchi, Y., Oliver, J., Ravetch, J., Poe, J., Haas, K. and Tedder, T. (2004) The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. The Journal of Experimental Medicine, 199, 1659-1669. doi:10.1084/jem.20040119</mixed-citation></ref><ref id="scirp.30589-ref59"><label>59</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lambert</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> Okada</surname><given-names> C. and Levy</given-names></name>,<name name-style="western"><surname> R. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2004</year>)<article-title>TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection</article-title><source> The Journal of Immunology</source><volume> 172</volume>,<fpage> 929</fpage>-<lpage>936</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Fossati-Jimack, L., Ioan-Facsinay, A., Reininger, L., Chicheportiche, Y., Watanabe, N., Saito, T., Hofhuis, F.M., Gessner, J.E., Schiller, C., Schmidt, R.E., Honjo, T., Verbeek, J.S. and Izui, S. (2000) Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an anti-erythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcγ receptor III. The Journal of Experimental Medicine, 191, 1293-1302. doi:10.1084/jem.191.8.1293</mixed-citation></ref><ref id="scirp.30589-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Nimmerjahn, F. and Ravetch, J. (2005) Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science, 310, 1510-1512. 
doi:10.1126/science.1118948</mixed-citation></ref><ref id="scirp.30589-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Markine-Goriaynoff, D. and Coutelier, J. (2002) Increased efficacy of the immunoglobulin G2a subclass in antibody-mediated protection against lactate dehydrogenase-elevating virus-induced polioencephalomyelitis revealed with switch mutants. Journal of Virology, 76, 432- 435. doi:10.1128/JVI.76.1.432-435.2002</mixed-citation></ref><ref id="scirp.30589-ref63"><label>63</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Giorgini</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> Brown</surname><given-names> H.J.</given-names></name>,<name name-style="western"><surname> Lock</surname><given-names> H.R.</given-names></name>,<name name-style="western"><surname> Nimmerjahn</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> Ravetch</surname><given-names> J.V.</given-names></name>,<name name-style="western"><surname> Verbeek</surname><given-names> J.S.</given-names></name>,<name name-style="western"><surname> Sacks</surname><given-names> S.H. and Robson</given-names></name>,<name name-style="western"><surname> M.G. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>FcγRIII and FcγRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies</article-title><source> The Journal of Immunology</source><volume> 181</volume>,<fpage> 8745</fpage>-<lpage>8752</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Da&amp;#235ron, M. (1997) Fc receptor biology. Annual Review of Immunology, 15, 203-234. 
doi:10.1146/annurev.immunol.15.1.203</mixed-citation></ref><ref id="scirp.30589-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Ravetch, J.V. and Kinet, J.P. (1991) Fc receptors. Annual Review of Immunology, 9, 457-492. 
doi:10.1146/annurev.iy.09.040191.002325</mixed-citation></ref><ref id="scirp.30589-ref66"><label>66</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Meyer</surname><given-names> D.</given-names></name>,<name name-style="western"><surname> Schiller</surname><given-names> C.</given-names></name>,<name name-style="western"><surname> Westermann</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Izui</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> Hazenbos</surname><given-names> W.</given-names></name>,<name name-style="western"><surname> Verbeek</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Schmidt</surname><given-names> R. and Gessner</given-names></name>,<name name-style="western"><surname> J. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1998</year>)<article-title>FcγRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia</article-title><source> Blood</source><volume> 92</volume>,<fpage> 3997</fpage>-<lpage>4002</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref67"><label>67</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Baudino</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Nimmerjahn</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> Azeredo da Silveira</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> Martinez-Soria</surname><given-names> E.</given-names></name>,<name name-style="western"><surname> Saito</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> Carroll</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Ravetch</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Verbeek</surname><given-names> J. and Izui</given-names></name>,<name name-style="western"><surname> S. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>Differential contribution of three activating IgG Fc receptors (FcγRI, FcγRIII, and FcγRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice</article-title><source> The Journal of Immunology</source><volume> 118</volume>,<fpage> 1948</fpage>-<lpage>1953</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref68"><label>68</label><mixed-citation publication-type="other" xlink:type="simple">Ioan-Facsinay, A., de Kimpe, S., Hellwig, S., van Lent, P., Hofhuis, F., van Ojik, H., Sedlik, C., da Silveira, S., Gerber, J., de Jong, Y., Roozendaal, R., Aarden, L., van den Berg, W., Saito, T., Mosser, D., Amigorena, S., Izui, S., van Ommen, G., van Vugt, M., van de Winkel, J. and Verbeek, J. (2002) Fcγ RI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity, 16, 391- 402. doi:10.1016/S1074-7613(02)00294-7</mixed-citation></ref><ref id="scirp.30589-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F. and Tedder, T.F. (2006) Antibody isotype-specific engagement of Fcγ receptors regulate B lymphocyte depletion during CD20 immunotherapy. The Journal of Experimental Medicine, 203, 743-753. 
doi:10.1084/jem.20052283</mixed-citation></ref><ref id="scirp.30589-ref70"><label>70</label><mixed-citation publication-type="other" xlink:type="simple">Kaneko, Y., Nimmerjahn, F., Madaio, M. and Ravetch, J. (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. The Journal of Experimental Medicine, 203, 789- 797. doi:10.1084/jem.20051900</mixed-citation></ref><ref id="scirp.30589-ref71"><label>71</label><mixed-citation publication-type="other" xlink:type="simple">Syed, S., Konrad, S., Wiege, K., Nieswandt, B., Nimmerjahn, F., Schmidt, R. and Gessner, J. (2009) Both FcγRIV and FcγRIII are essential receptors mediating type II and type III autoimmune responses via FcRγ-LAT- dependent generation of C5a. European Journal of Immunology, 39, 3343-3356. doi:10.1002/eji.200939884</mixed-citation></ref><ref id="scirp.30589-ref72"><label>72</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pricop</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Redecha</surname><given-names> P.</given-names></name>,<name name-style="western"><surname> Teillaud</surname><given-names> J.-L.</given-names></name>,<name name-style="western"><surname> Frey</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Fridman</surname><given-names> W.H.</given-names></name>,<name name-style="western"><surname> Sautès-Fridman</surname><given-names> C. and Salmon</given-names></name>,<name name-style="western"><surname> J.E. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines</article-title><source> The Journal of Immunology</source><volume> 166</volume>,<fpage> 531</fpage>-<lpage>537</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref73"><label>73</label><mixed-citation publication-type="other" xlink:type="simple">Schmidt, R. and Gessner, J. (2005) Fc receptors and their interaction with complement in autoimmunity. Immunology Letters, 100, 56-67. 
doi:10.1016/j.imlet.2005.06.022</mixed-citation></ref><ref id="scirp.30589-ref74"><label>74</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tridandapani</surname><given-names> S.</given-names></name>,<name name-style="western"><surname> Wardrop</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> Baran</surname><given-names> C.P.</given-names></name>,<name name-style="western"><surname> Wang</surname><given-names> Y.</given-names></name>,<name name-style="western"><surname> Opalek</surname><given-names> J.M.</given-names></name>,<name name-style="western"><surname> Caligiuri</surname><given-names> M.A. and Marsh</given-names></name>,<name name-style="western"><surname> C.B. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2003</year>)<article-title>TGF-β1 suppresses myeloid Fcγ receptor function by regulating the expression and function of the common γ-subunit</article-title><source> The Journal of Immunology</source><volume> 170</volume>,<fpage> 4572</fpage>-<lpage>4577</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref75"><label>75</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Salmon</surname><given-names> J.E.</given-names></name>,<name name-style="western"><surname> Browle</surname><given-names> N.L.</given-names></name>,<name name-style="western"><surname> Edberg</surname><given-names> J.C. and Kimberly</given-names></name>,<name name-style="western"><surname> R.P. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1991</year>)<article-title>Fcγ receptor III induces actin polymerization in human neutrophils and primes phagocytosis mediated by Fcγ receptor II</article-title><source> The Journal of Immunology</source><volume> 146</volume>,<fpage> 997</fpage>-<lpage>1004</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref76"><label>76</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kocher</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Siegel</surname><given-names> M.E.</given-names></name>,<name name-style="western"><surname> Edberg</surname><given-names> J.C. and Kimberly</given-names></name>,<name name-style="western"><surname> R.P. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>Cross-linking of Fcγ receptor IIa and Fcγ receptor IIIb induces different proadhesive phenotypes on human neutrophils</article-title><source> The Journal of Immunology</source><volume> 159</volume>,<fpage> 3940</fpage>-<lpage>3948</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref77"><label>77</label><mixed-citation publication-type="other" xlink:type="simple">Ortiz-Stern, A. and Rosales, C. (2005) FcγRIIIB stimulation promotes β1 integrin activation in human neutrophils. Journal of Leukocyte Biology, 77, 787-799. 
doi:10.1189/jlb.0504310</mixed-citation></ref><ref id="scirp.30589-ref78"><label>78</label><mixed-citation publication-type="other" xlink:type="simple">Rivas-Fuentes, S., García-García, E., Nieto-Casta&amp;#241eda, G. and Rosales, C. (2010) Fcγ receptors exhibit different phagocytosis potential in human neutrophils. Cellular Immunology, 263, 114-121. 
doi:10.1016/j.cellimm.2010.03.006</mixed-citation></ref><ref id="scirp.30589-ref79"><label>79</label><mixed-citation publication-type="other" xlink:type="simple">García-García, E., Nieto-Casta&amp;#241eda, G., Ruiz-Salda&amp;#241a, M., Mora, N. and Rosales, C. (2009) FcγRIIA and FcγRIIIB mediate nuclear factor activation through separate signaling pathways in human neutrophils. The Journal of Immunology, 182, 4547-4556. 
doi:10.4049/jimmunol.0801468</mixed-citation></ref><ref id="scirp.30589-ref80"><label>80</label><mixed-citation publication-type="other" xlink:type="simple">Shields, R., Namenuk, A., Hong, K., Meng, Y., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., Fox, J. and Presta, L. (2001) High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. The Journal of Biological Chemistry, 276, 6591- 6604. doi:10.1074/jbc.M009483200</mixed-citation></ref><ref id="scirp.30589-ref81"><label>81</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mizuochi</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> Hamako</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Nose</surname><given-names> M. and Titani</given-names></name>,<name name-style="western"><surname> K. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>Structural changes in the oligosaccharide chains of IgG in autoimmune MRL/Mp-lpr/lpr mice</article-title><source> The Journal of Immunology</source><volume> 145</volume>,<fpage> 1794</fpage>-<lpage>1798</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref82"><label>82</label><mixed-citation publication-type="other" xlink:type="simple">Rook, G., Steele, J., Brealey, R., Whyte, A., Isenberg, D., Sumar, N., Nelson, J., Bodman, K., Young, A. and Roitt, I. (1991) Changes in IgG glycoform levels are associated with remission of arthritis during pregnancy. Journal of Autoimmunity, 4, 779-794. 
doi:10.1016/0896-8411(91)90173-A</mixed-citation></ref><ref id="scirp.30589-ref83"><label>83</label><mixed-citation publication-type="other" xlink:type="simple">van de Geijn, F., Wuhrer, M., Selman, M., Willemsen, S., de Man, Y., Deelder, A., Hazes, J. and Dolhain, R. (2009) Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Research &amp; Therapy, 11, R193. doi:10.1186/ar2892</mixed-citation></ref><ref id="scirp.30589-ref84"><label>84</label><mixed-citation publication-type="other" xlink:type="simple">Jefferis, R. (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nature Reviews Drug Discovery, 8, 226-234. doi:10.1038/nrd2804</mixed-citation></ref><ref id="scirp.30589-ref85"><label>85</label><mixed-citation publication-type="other" xlink:type="simple">Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N. and Shitara, K. (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. The Journal of Biological Chemistry, 278, 3466-3473. 
doi:10.1074/jbc.M210665200</mixed-citation></ref><ref id="scirp.30589-ref86"><label>86</label><mixed-citation publication-type="other" xlink:type="simple">Shields, R., Lai, J., Keck, R., O’Connell, L., Hong, K., Meng, Y., Weikert, S. and Presta, L. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. The Journal of Biological Chemistry, 277, 26733-26740. doi:10.1074/jbc.M202069200</mixed-citation></ref><ref id="scirp.30589-ref87"><label>87</label><mixed-citation publication-type="other" xlink:type="simple">Anthony, R., Wermeling, F., Karlsson, M. and Ravetch, J. (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proceedings of the National Academy of Sciences of the United States of America, 105, 19571-19578. 
doi:10.1073/pnas.0810163105</mixed-citation></ref><ref id="scirp.30589-ref88"><label>88</label><mixed-citation publication-type="other" xlink:type="simple">Scallon, B., Tam, S., McCarthy, S., Cai, A. and Raju, T. (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Molecular Immunology, 44, 1524-1532. 
doi:10.1016/j.molimm.2006.09.005</mixed-citation></ref><ref id="scirp.30589-ref89"><label>89</label><mixed-citation publication-type="other" xlink:type="simple">Bruhns, P., Samuelsson, A., Pollard, J. and Ravetch, J. (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity, 18, 573-581. 
doi:10.1016/S1074-7613(03)00080-3</mixed-citation></ref><ref id="scirp.30589-ref90"><label>90</label><mixed-citation publication-type="other" xlink:type="simple">Tackenberg, B., Jelcic, I., Baerenwaldt, A., Oertel, W.H., Sommer, N., Nimmerjahn, F. and Lunemann, J.D. (2009) Impaired inhibitory FcγRIIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proceedings of the National Academy of Sciences of the United States of America, 106, 4788-4792. 
doi:10.1073/pnas.0807319106</mixed-citation></ref><ref id="scirp.30589-ref91"><label>91</label><mixed-citation publication-type="other" xlink:type="simple">Agrawal, A., Singh, P., Bottazzi, B., Garlanda, C. and Mantovani, A. (2009) Pattern recognition by pentraxins. Advances in Experimental Medicine and Biology, 653, 98- 116. doi:10.1007/978-1-4419-0901-5_7</mixed-citation></ref><ref id="scirp.30589-ref92"><label>92</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bharadwaj</surname><given-names> D.</given-names></name>,<name name-style="western"><surname> Mold</surname><given-names> C.</given-names></name>,<name name-style="western"><surname> Markham</surname><given-names> E. and Du Clos</given-names></name>,<name name-style="western"><surname> T. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Serum amyloid P component binds to Fc gamma receptors and opsonizes particles for phagocytosis</article-title><source> The Journal of Immunology</source><volume> 166</volume>,<fpage> 6735</fpage>-<lpage>6741</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref93"><label>93</label><mixed-citation publication-type="other" xlink:type="simple">Lu, J., Marnell, L., Marjon, K., Mold, C., Du Clos, T. and Sun, P. (2008) Structural recognition and functional activation of FcγR by innate pentraxins. Nature, 456, 989- 992. doi:10.1038/nature07468</mixed-citation></ref><ref id="scirp.30589-ref94"><label>94</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marjon</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> Marnell</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Mold</surname><given-names> C. and Du Clos</given-names></name>,<name name-style="western"><surname> T. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2009</year>)<article-title>Macrophages activated by C-reactive protein through Fcγ RI transfer suppression of immune thrombocytopenia</article-title><source> The Journal of Immunology</source><volume> 182</volume>,<fpage> 1397</fpage>-<lpage>1403</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref95"><label>95</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Thomas-Rudolph</surname><given-names> D.</given-names></name>,<name name-style="western"><surname> Du Clos</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> Snapper</surname><given-names> C. and Mold</given-names></name>,<name name-style="western"><surname> C. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>C-reactive protein enhances immunity to Streptococcus pneumoniae by targeting uptake to FcγR on dendritic cells</article-title><source> The Journal of Immunology</source><volume> 178</volume>,<fpage> 7283</fpage>-<lpage>7291</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.30589-ref96"><label>96</label><mixed-citation publication-type="other" xlink:type="simple">Bharadwaj, D., Stein, M., Volzer, M., Mold, C. and Du Clos, T. (1999) The major receptor for C-reactive protein on leukocytes is Fc gamma receptor II. The Journal of Experimental Medicine, 190, 585-590. 
doi:10.1084/jem.190.4.585</mixed-citation></ref><ref id="scirp.30589-ref97"><label>97</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rodriguez</surname><given-names> W.</given-names></name>,<name name-style="western"><surname> Mold</surname><given-names> C.</given-names></name>,<name name-style="western"><surname> Kataranovski</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Hutt</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Marnell</surname><given-names> L.</given-names></name>,<name name-style="western"><surname> Verbeek</surname><given-names> J. and Du Clos</given-names></name>,<name name-style="western"><surname> T. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2007</year>)<article-title>C-reactive protein-mediated suppression of nephrotoxic nephritis: Role of macrophages, complement, and Fcγ receptors</article-title><source> The Journal of Immunology</source><volume> 178</volume>,<fpage> 530</fpage>-<lpage>538</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref></ref-list></back></article>